about
Emerging technologies for studying DNA methylation for the molecular diagnosis of cancerDevelopment of a Premature Stop Codon-detection method based on a bacterial two-hybrid system.DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterationsEpigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomasBrain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosomeThe CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype SwitchingDiagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives.The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomasEpigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA.Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome.MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.MLPA mutation detection in Argentine HNPCC and FAP families.Detection of deletions and duplications in the Duchenne muscular dystrophy gene by the molecular method MLPA in the first Argentine affected families.Epigenetic profiling for the molecular classification of metastatic brain tumorsBrain metastasis DNA methylomes, a novel resource for the identification of biological and clinical featuresEpigenetic Classifiers for Precision Diagnosis of Brain TumorsAlternative splicing and cancer metastasis: prognostic and therapeutic applicationsClinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerClinicopathological Features of Triple-Negative Breast Cancer Epigenetic SubtypesB7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma
P50
Q28087759-B83C700B-2EE6-4D0B-9C01-E1B4E1491C2AQ33256142-F9405CA4-293F-4202-81AF-01F9E6500FC4Q34359695-1F593BA7-D814-416E-B88E-57C2F7A5262FQ35018167-A2A1607C-CD3D-4D43-9CCC-8FFB09825E85Q35023463-61B02F1F-D3C3-4793-9E41-267BC02356FFQ36054438-399DB06D-0AE1-4BC5-8EBB-53E62D9BC72CQ38152782-FF2E6FC5-C40C-4DF7-A463-F8280D01C582Q38660042-1BAE8356-4819-4298-8879-1177CC007A5BQ38696187-3E7235D2-B6E2-4CE7-940E-CA20F395FF00Q38847201-7E95D477-18D9-4726-B6BA-01F39C5D1020Q39690990-C0A70F52-EC6E-48E5-B14D-5C383BD8FFD0Q41682967-6FCE3185-E6BD-46C4-8865-EDA4521802CAQ45990980-D4AB7E81-22DC-4776-9320-7BC6B7F90F0DQ54419889-FD4D32C3-E323-4AC1-8D8F-9B638DF1A54FQ54538552-5A022DF9-8387-4D8F-BE72-805E052FDE06Q58608173-C6BB6928-D178-4096-88DC-51FD9A8DDB30Q58608725-B04100A2-9707-4BA2-8479-54B17B153254Q64098767-BC0A96C4-5159-4EE0-807E-1A9EE6D01B29Q88912942-1884B8DF-3A1E-4543-BB31-601FEFEC81B8Q92162167-20D76F8C-1E41-4A40-8405-CF6BB4287AC7Q92162199-C1F6B476-F33A-4EDF-952B-EFE04D12804FQ92637402-FCA2BDEA-1543-4DEF-B4E1-B2BFFA79E01A
P50
description
researcher ORCID ID = 0000-0002-3258-8852
@en
wetenschapper
@nl
name
Diego M Marzese
@ast
Diego M Marzese
@en
Diego M Marzese
@nl
type
label
Diego M Marzese
@ast
Diego M Marzese
@en
Diego M Marzese
@nl
prefLabel
Diego M Marzese
@ast
Diego M Marzese
@en
Diego M Marzese
@nl
P106
P21
P31
P496
0000-0002-3258-8852